BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 30309219)

  • 21. Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis.
    Hu SX; He XH; Dong M; Jia B; Zhou SY; Yang JL; Yang S; Zhang CG; Liu P; Qin Y; Gui L
    Med Oncol; 2015 Sep; 32(9):224. PubMed ID: 26219572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosimetric parameters associated with conductive or sensorineural hearing loss 5 years after intensity-modulated radiation therapy in nasopharyngeal carcinoma.
    Zhu W; Chen F; Li J; Wang W; Zhang H; Yang G; Zou L; Zhu Y; Yuan W; Ding H; Song X; Wang S
    Acta Otolaryngol; 2019 Mar; 139(3):263-268. PubMed ID: 30870056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensity-modulated radiation therapy achieves better local control compared to three-dimensional conformal radiation therapy for T4-stage nasopharyngeal carcinoma.
    Chen JL; Huang YS; Kuo SH; Hong RL; Ko JY; Lou PJ; Wang CW
    Oncotarget; 2017 Feb; 8(8):14068-14077. PubMed ID: 27764778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
    Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
    BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognoses and long-term outcomes of nasopharyngeal carcinoma in Han and Uyghur patients treated with intensity-modulated radiotherapy in the Xinjiang Autonomous Region of China.
    Wang R; Tan Y; Wang X; Ma L; Wang D; Hu Y; Qin Y; Liu K; Chang C; Yu J
    PLoS One; 2014; 9(11):e111145. PubMed ID: 25375129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update report of T4 classification nasopharyngeal carcinoma after intensity-modulated radiotherapy: an analysis of survival and treatment toxicities.
    Cao CN; Luo JW; Gao L; Yi JL; Huang XD; Wang K; Zhang SP; Qu Y; Li SY; Xiao JP; Zhang Z; Xu GZ
    Oral Oncol; 2015 Feb; 51(2):190-4. PubMed ID: 25434585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy.
    Mao YP; Tang LL; Chen L; Sun Y; Qi ZY; Zhou GQ; Liu LZ; Li L; Lin AH; Ma J
    Chin J Cancer; 2016 Dec; 35(1):103. PubMed ID: 28031050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Irradiation-induced nasopharyngeal necrosis (INN) in newly diagnosed nasopharyngeal carcinoma treated by intensity-modulated radiation therapy: clinical characteristics and the influence of treatment strategies.
    Xu Y; Liu Y; Wang Z; Wang J; Zhang J; Chen X; Wu R; Liu Q; Qu Y; Wang K; Huang X; Luo J; Gao L; Xu G; Zhang Y; Yi J
    Radiat Oncol; 2022 Jan; 17(1):13. PubMed ID: 35062991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Nomogram for Patients with Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy.
    Wu S; Xia B; Han F; Xie R; Song T; Lu L; Yu W; Deng X; He Q; Zhao C; Xie C
    PLoS One; 2015; 10(8):e0134491. PubMed ID: 26248338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area.
    Lv JW; Chen YP; Huang XD; Zhou GQ; Chen L; Li WF; Tang LL; Mao YP; Guo Y; Xu RH; Ma J; Sun Y
    Cancer; 2017 Sep; 123(18):3540-3549. PubMed ID: 28493307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Geographical disparities in the prognosis of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a large institution-based cohort study from an endemic area.
    Lin ST; Meng DF; Yang Q; Wang W; Peng LX; Zheng LS; Qiang YY; Mei Y; Xu L; Li CZ; Peng XS; Hu H; Lang YH; Liu ZJ; Wang MD; Li HF; Huang BJ; Qian CN; Sun R
    BMJ Open; 2020 Nov; 10(11):e037150. PubMed ID: 33172940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic scoring system for locoregional control among the patients with nasopharyngeal carcinoma treated by intensity-modulated radiotherapy.
    Tao CJ; Liu X; Tang LL; Mao YP; Chen L; Li WF; Yu XL; Liu LZ; Zhang R; Lin AH; Ma J; Sun Y
    Chin J Cancer; 2013 Sep; 32(9):494-501. PubMed ID: 23981849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up.
    Zhang MX; Li J; Shen GP; Zou X; Xu JJ; Jiang R; You R; Hua YJ; Sun Y; Ma J; Hong MH; Chen MY
    Eur J Cancer; 2015 Nov; 51(17):2587-95. PubMed ID: 26318726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiation Therapy.
    Lu S; Wei J; Sun F; Xiao W; Cai R; Zhen Z; Zhu J; Wang J; Huang J; Lu L; Sun X; Gao Y
    Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):45-51. PubMed ID: 30244159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The study of clinical long-term effect and prognostic factors in nasopharyngeal carcinoma after intensity modulated radiation therapy].
    Liu K; Han Y; Ma B
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Nov; 27(21):1177-83. PubMed ID: 24616996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term survival outcomes and adverse effects of nasopharyngeal carcinoma patients treated with IMRT in a non-endemic region: a population-based retrospective study.
    Xu M; Zang J; Luo S; Wang J; Li X
    BMJ Open; 2021 Aug; 11(8):e045417. PubMed ID: 34341036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
    Liu YP; Wen YH; Tang J; Wei Y; You R; Zhu XL; Li J; Chen L; Ling L; Zhang N; Zou X; Hua YJ; Chen YM; Chen L; Lu LX; Chen MY; Wen WP
    Lancet Oncol; 2021 Mar; 22(3):381-390. PubMed ID: 33600761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postirradiation otitis media with effusion in nasopharyngeal carcinoma patients treated by intensity-modulated radiotherapy.
    Hsin CH; Chen TH; Liang KL; Tseng HC; Liu WS
    Laryngoscope; 2013 Sep; 123(9):2148-53. PubMed ID: 23835775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
    Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM
    Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of long-term survival outcomes and failure patterns of patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: a retrospective analysis.
    Zhao W; Lei H; Zhu X; Li L; Qu S; Liang X
    Oncotarget; 2016 Dec; 7(52):86914-86925. PubMed ID: 27894100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.